Ligelizumab for Chronic Spontaneous Urticaria

Ligelizumab for Chronic Spontaneous Urticaria

Background: In the majority of patients with chronic spontaneous urticaria, most currently available therapies do not result in complete symptom control. Ligelizumab is a nextgeneration high-affinity humanized monoclonal anti-IgE antibody. Data are limited regarding...